195 related articles for article (PubMed ID: 33160265)
1. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
Rosen K; Prasad V; Chen EY
Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
[TBL] [Abstract][Full Text] [Related]
2. Informative censoring of surrogate end-point data in phase 3 oncology trials.
Gilboa S; Pras Y; Mataraso A; Bomze D; Markel G; Meirson T
Eur J Cancer; 2021 Aug; 153():190-202. PubMed ID: 34186504
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
4. Equal censoring but still informative: When the reasons for censoring differ between treatment arms.
Olivier T; Prasad V
Eur J Cancer; 2024 Apr; 201():113942. PubMed ID: 38382151
[TBL] [Abstract][Full Text] [Related]
5. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
Campigotto F; Weller E
J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
[TBL] [Abstract][Full Text] [Related]
6. The role of censoring on progression free survival: oncologist discretion advised.
Prasad V; Bilal U
Eur J Cancer; 2015 Nov; 51(16):2269-71. PubMed ID: 26259493
[TBL] [Abstract][Full Text] [Related]
7. Influence of censoring on conclusions of trials for women with metastatic breast cancer.
Templeton AJ; Ace O; Amir E; Vera-Badillo F; Ocana A; Pond GR; Tannock IF
Eur J Cancer; 2015 Apr; 51(6):721-4. PubMed ID: 25728257
[TBL] [Abstract][Full Text] [Related]
8. Detecting an overall survival benefit that is derived from progression-free survival.
Broglio KR; Berry DA
J Natl Cancer Inst; 2009 Dec; 101(23):1642-9. PubMed ID: 19903805
[TBL] [Abstract][Full Text] [Related]
9. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
[TBL] [Abstract][Full Text] [Related]
10. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.
Olivier T; Haslam A; Prasad V
J Clin Epidemiol; 2021 Nov; 139():80-86. PubMed ID: 34311054
[TBL] [Abstract][Full Text] [Related]
11. Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.
Royston P; Parmar MK; Altman DG
J Natl Cancer Inst; 2008 Jan; 100(2):92-7. PubMed ID: 18182621
[TBL] [Abstract][Full Text] [Related]
12. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
13. Estimation of colorectal adenoma recurrence with dependent censoring.
Hsu CH; Long Q; Alberts DS
BMC Med Res Methodol; 2009 Sep; 9():66. PubMed ID: 19788750
[TBL] [Abstract][Full Text] [Related]
14. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
15. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.
Morita S; Sakamaki K; Yin G
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25956357
[TBL] [Abstract][Full Text] [Related]
16. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
18. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.
Martini A; Yu M; Raggi D; Joshi H; Fallara G; Montorsi F; Necchi A; Galsky MD
Cancer; 2022 Aug; 128(15):2892-2897. PubMed ID: 35553053
[TBL] [Abstract][Full Text] [Related]
20. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
